Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.76 |
| ▸ | RAB9A | P51151 | 4/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | NPC1 | O15118 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21067416 | 0.86 | LTA4H (1.00) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL8285853 | 0.85 | MEN1 (0.60) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3224230 | 0.85 | LTA4H (0.76) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4075780 | 0.85 | LTA4H (0.84) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL5659338 | 0.85 | LTA4H (0.76) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL2170643 | 0.85 | LTA4H (0.76) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL7933622 | 0.84 | LTA4H (0.61) | LTA4HMEN1KMT2A | |
| SCHEMBL4666205 | 0.84 | RAB9A (0.74) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL3505916 | 0.84 | LTA4H (0.78) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL21295527 | 0.83 | MEN1 (0.77) | LTA4HRAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | LTA4H 184/4885RAB9A 3098/4885SMN1; SMN2 313/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | LTA4H 207/4885RAB9A 1619/4885SMN1; SMN2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.